A detailed history of Strategy Asset Managers LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Strategy Asset Managers LLC holds 1,643 shares of ABBV stock, worth $292,470. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,643
Holding current value
$292,470
% of portfolio
0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$163.84 - $199.33 $269,189 - $327,499
1,643 New
1,643 $324,000
Q1 2023

May 02, 2023

SELL
$144.61 - $166.54 $5,639 - $6,495
-39 Reduced 2.03%
1,885 $300,000
Q4 2022

Jan 13, 2023

SELL
$138.31 - $165.87 $13,554 - $16,255
-98 Reduced 4.85%
1,924 $311,000
Q3 2022

Oct 11, 2022

BUY
$134.21 - $153.93 $271,372 - $311,246
2,022 New
2,022 $271,000
Q3 2019

Nov 13, 2019

SELL
$62.98 - $75.72 $351,554 - $422,669
-5,582 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $429,283 - $548,725
-6,534 Closed
0 $0
Q1 2019

May 08, 2019

BUY
$77.14 - $90.79 $504,032 - $593,221
6,534 New
6,534 $527,000
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $1.41 Million - $1.74 Million
-18,130 Closed
0 $0
Q3 2018

Nov 01, 2018

SELL
$88.91 - $98.84 $2.63 Million - $2.93 Million
-29,605 Reduced 62.02%
18,130 $0
Q2 2018

Aug 07, 2018

SELL
$89.78 - $106.23 $180,906 - $214,053
-2,015 Reduced 4.05%
47,735 $4.42 Million
Q1 2018

May 03, 2018

BUY
$92.01 - $123.21 $2.43 Million - $3.25 Million
26,367 Added 112.76%
49,750 $4.71 Million
Q4 2017

Jan 29, 2018

SELL
$89.56 - $98.21 $94,127 - $103,218
-1,051 Reduced 4.3%
23,383 $2.26 Million
Q3 2017

Nov 06, 2017

SELL
$69.85 - $89.22 $10,687 - $13,650
-153 Reduced 0.62%
24,434 $2.17 Million
Q2 2017

Aug 07, 2017

BUY
N/A
24,587
24,587 $1.78 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Strategy Asset Managers LLC Portfolio

Follow Strategy Asset Managers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategy Asset Managers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategy Asset Managers LLC with notifications on news.